产品封面图
文献支持

5637细胞系

收藏
  • ¥1320
  • BHcell(博辉生物)
  • H-C014
  • 2026年01月14日
    avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 规格

      T25

    5637细胞5637人膀胱癌细胞

    Cell line name 5637

    Accession CVCL_0126

    Resource Identification Initiative To cite this cell line use: 5637 (RRID:CVCL_0126)

    Comments Part of: BLA-40 bladder carcinoma cell line panel.

    Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

    Part of: COSMIC cell lines project.

    Part of: ERK genetic alteration cell panel (ATCC TCP-1033).

    Part of: UBC-40 urothelial bladder cancer cell line index.

    Doubling time: 23 hours (PubMed=26055179); ~24 hours (DSMZ=ACC-35).

    Microsatellite instability: Stable (MSS) (Sanger).

    Omics: Array-based CGH.

    Omics: CNV analysis.

    Omics: Deep exome analysis.

    Omics: Deep quantitative proteome analysis.

    Omics: DNA methylation analysis.

    Omics: GPI-anchored proteins analysis by proteomics.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis by microarray.

    Omics: Transcriptome analysis by RNAseq.

    Misspelling: HTB9; Note=Based on the ATCC catalog number.

    Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.

    PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

    Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

    A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

    Cancer Res. 70:2158-2164(2010)

     

    PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

    Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

    The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

    Nature 483:603-607(2012)

     

    PubMed=23401075; DOI=10.1002/path.4176

    Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L., Kwiatkowski D.J.

    TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.

    J. Pathol. 230:17-27(2013)

     

    PubMed=24367658; DOI=10.1371/journal.pone.0084411; PMCID=PMC3867501

    Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.

    Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

    PLoS ONE 8:E84411-E84411(2013)

     

    PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057

    Hurst C.D., Platt F.M., Knowles M.A.

    Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

    Eur. Urol. 65:367-369(2014)

     

    PubMed=24459064; DOI=10.1007/s13277-013-1604-3

    Pinto-Leite R., Carreira I.M., Melo J.B., Ferreira S.I., Ribeiro I.P., Ferreira J., Filipe M., Bernardo C., Arantes-Rodrigues R., Oliveira P., Santos L.

    Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.

    Tumor Biol. 35:4599-4617(2014)

     

    PubMed=25997541; DOI=10.1186/s12864-015-1450-3; PMCID=PMC4470036

    Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B., Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G., Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D., Chanock S.J., Valencia A., Real F.X.

    The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

    BMC Genomics 16:403.1-403.16(2015)

     

    PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002; PMCID=PMC4487788

    Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M., Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.

    Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.

    Transl. Oncol. 8:210-216(2015)

     

    PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008

    Masuishi Y., Kimura Y., Arakawa N., Hirano H.

    Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.

    J. Proteomics 139:77-83(2016)

     

    PubMed=27141528; DOI=10.1016/j.dib.2016.04.001; PMCID=PMC4838930

    Masuishi Y., Kimura Y., Arakawa N., Hirano H.

    Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.

    Data Brief 7:1302-1305(2016)

     

    PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

    Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miro T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

    A landscape of pharmacogenomic interactions in cancer.

    Cell 166:740-754(2016)

     

    PubMed=27270441; DOI=10.1038/onc.2016.172; PMCID=PMC5140783

    Nickerson M.L., Witte N., McGee Im K., Turan S., Owens C.R., Misner K., Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.

    Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.

    Oncogene 36:35-46(2017)

     

    PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350

    Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.

    Systematic review: characteristics and preclinical uses of bladder cancer cell lines.

    Bladder Cancer 4:169-183(2018)

     

    PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

    Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

    An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

    Cancer Res. 79:1263-1273(2019)

     

    PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

    Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

    Next-generation characterization of the Cancer Cell Line Encyclopedia.

    Nature 569:503-508(2019)

     

    PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775

    Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

    Pan-cancer proteomic map of 949 human cell lines.

    Cancer Cell 40:835-849.e8(2022)

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    *发表【中文论文】请标注:由博辉生物科技(广州)有限公司提供; *发表【英文论文】请标注:From Bohui Biological Technology (Guangzhou) Co., Ltd.

    相关实验
    • 【求助】求助!HepG-2细胞系内的p53是野生型的么?

      edwardellen 求助!!! 本人菜鸟,最近开始接触凋亡相关信号,在HepG-2中做实验,有一点很困惑,HepG-2中的p53是野生型的还是突变型的?还是两者都存在?查了一些资料,有些文章之间表达的意思模凌两可。困惑啊! 哪位好心的达人能给我一个确定的答案呢? 另外,是否有做p53相关的牛人能告诉我P53在哪些实验用肿瘤细胞系中是野生型的,在哪些是突变型的? 谢谢!谢谢!谢谢! doctormy

    • 【求助】哪个细胞系是研究细胞凋亡的理想工具?

      shao74 最近在做细胞凋亡方面的实验,碰到的问题是手头上的细胞系对凋亡不是很敏感,所以不知哪位有更好的建议,谢谢! freecell 这个不好说啊,看你主要做哪个组织的细胞凋亡,什么因素引起的细胞凋亡。 Fasta921 所以要自己筛选敏感的细胞株啊,不同细胞系对同种基因或药物的耐受性不一样的。 goldendoctor Hela 是比较常用

    • 细胞系的建立

      各种已被命名和经过细胞生物学鉴定的细胞系或细胞株 ,都是一些形态比较均一、生长增殖比较稳定的和生物 性状清楚的细胞群。因此凡符合上述情况的细胞群也可 给以相应的名称,即文献中常称之为已鉴定的细胞(Certified Cells)。已鉴定的细胞可用于各种实验研究和生产生物制品。当前世界上已建的各种细胞系(株)已难胜数,我国也建有百种以上,并在不断增长中。体外培养细胞的种类和命名 体外培养细胞的名称,随培养细胞技术的发展和细胞种类的增多而演变。最早采用的名称为细胞株(Cell strain),以后

    图标技术资料

    资料下载:

    5637(BH-C014).docx 附 (下载 0 次)

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥1300
    上海匹拓生物科技有限公司
    2026年01月21日询价
    询价
    ATCC细胞库
    2025年11月03日询价
    询价
    北京中源合聚生物科技有限公司
    2026年01月22日询价
    ¥1400
    上海盖宁生物科技有限公司
    2026年01月27日询价
    文献支持
    5637细胞系
    ¥1320